Efficacy of ex vivo activated and expanded natural killer cells and T lymphocytes for colorectal cancer patients

Subramani,Baskar; Pullai,Chithra Ramanathan; Krishnan,Kohila; Sugadan,Sheela Devi; Deng,Xuewen; Hiroshi,Terunuma; Ratnavelu,Kananathan

doi:10.3892/br.2014.264

Efficacy of ex vivo activated and expanded natural killer cells and T lymphocytes for colorectal cancer patients

Authors:
- Baskar Subramani
- Chithra Ramanathan Pullai
- Kohila Krishnan
- Sheela Devi Sugadan
- Xuewen Deng
- Terunuma Hiroshi
- Kananathan Ratnavelu
View Affiliations

Affiliations: Nichi‑Asia Life Science, Sdn. Bhd., Petaling Jaya 47810, Malaysia, Biotherapy Institute of Japan, Tokyo 135‑0051, Japan, Nilai Cancer Institute (NCI) Hospital, Nilai 71800, Malaysia
Published online on: March 26, 2014 https://doi.org/10.3892/br.2014.264
Pages: 505-508

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Immune cell‑based therapies using natural killer (NK) cells and cytotoxic T cells are under constant scrutiny, with the aim to design an effective and reduced‑toxicity therapy, which will benefit patients via improved quality of life and improved prognosis. Four patients with stage IV colon cancer were administered 1, 3, 5 and 6 effector cell intravenous infusions, respectively. Peripheral blood was collected from the patients and the ex vivo activation and expansion of NK and T cells was performed in good manufacturing practice‑certified clean rooms for ~12‑15 days. Immunophenotypic analysis of the peripheral blood mononuclear cells (PBMCs) and expanded NK and T cells was conducted using flow cytometry and the patients were followed up. On average, 4.8x107 initial PBMCs and 2.7x109 total expanded cells were obtained. The intravenous infusions of the expanded cells were not accompanied by adverse reactions. Improved prognosis, reflected by a considerable decrease in the cancer markers, accompanied by an improved quality of life in the patients were observed. In conclusion, potential strategies are currently under development for the large‑scale production of effectors cells; therefore, autologous immune enhancement therapy (AIET) may be considered as a viable approach to cancer treatment.

View Figures

View References

1	Ministry of Health Malaysia, National Cancer Registry. Malaysian cancer statistics - data and figure peninsular Malaysia. 2006, http://www.makna.org.my/PDF/MalaysiaCancerStatistics.pdfuri. Accessed, May 01, 2013
2	Cai GX and Cai SJ: Multi-modality treatment of colorectal liver metastases. World J Gastroenterol. 18:16–24. 2012. View Article : Google Scholar : PubMed/NCBI
3	Amersi F, Stamos MJ and Ko CY: Palliative care for colorectal cancer. Surg Oncol Clin N Am. 13:467–477. 2004. View Article : Google Scholar
4	Ronnekleiv-Kelly SM and Kennedy GD: Management of stage IV rectal cancer: palliative options. World J Gastroenterol. 17:835–847. 2011. View Article : Google Scholar : PubMed/NCBI
5	Cunningham D, Atkin W, Lenz HJ, et al: Colorectal cancer. Lancet. 375:1030–1047. 2010. View Article : Google Scholar
6	Kannagi R: Carbohydrate antigen sialyl Lewis a - its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med J. 30:189–209. 2007.PubMed/NCBI
7	Sato H, Usuda N, Kuroda M, et al: Significance of serum concentrations of E-selectin and CA19–9 in the prognosis of colorectal cancer. Jpn J Clin Oncol. 40:1073–1080. 2010.PubMed/NCBI
8	Wasserberg N and Kaufman HS: Palliation of colorectal cancer. Surg Oncol. 16:299–310. 2007. View Article : Google Scholar
9	Rosenberg SA, Restifo NP, Yamg JC, et al: Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 8:299–308. 2008. View Article : Google Scholar : PubMed/NCBI
10	Hunder NN, Wallen H, Cao J, et al: Treatment of metastatic melanoma with autologous CD4⁺T cells against NY-ESO-1. N Engl J Med. 358:2698–2703. 2008. View Article : Google Scholar : PubMed/NCBI
11	Srivastava S, Lundqvist A and Childs RW: Natural killer cell immunotherapy for cancer: a new hope. Cytotherapy. 10:775–783. 2008. View Article : Google Scholar : PubMed/NCBI
12	Alves PC, Andrade LA, Petta CA, et al: Ex vivo expansion of CD56⁺NK and NKT-like lymphocytes from peripheral blood mononuclear cells of patients with ovarian neoplasia. Scand J Immunol. 74:244–252. 2011.PubMed/NCBI
13	Somanchi SS, Senyukov VV, Denman CJ and Lee DA: Expansion, purification, and functional assessment of human peripheral blood NK cells. J Vis Exp. 25402011.PubMed/NCBI
14	Terunuma H, Deng X, Dewan Z, et al: Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections. Int Rev Immunol. 27:93–110. 2008. View Article : Google Scholar : PubMed/NCBI
15	Teschner D, Wenzel G, Distler E, et al: In vitro stimulation and expansion of human tumour-reactive CD8⁺cytotoxic T lymphocytes by anti-CD3/CD28/CD137 magnetic beads. Scand J Immunol. 74:155–164. 2011.PubMed/NCBI
16	Hippen KL, Merkel SC, Schirm DK, et al: Massive ex vivo expansion of human natural regulatory T cells (T_regs) with minimal loss of in vivo functional activity. Sci Transl Med. 3:83ra412011. View Article : Google Scholar : PubMed/NCBI
17	Takada M, Terunuma H, Deng X, et al: Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer. 18:64–67. 2011. View Article : Google Scholar : PubMed/NCBI
18	Dewan MZ, Terunuma H, Toi M, Tanaka Y, et al: Potential role of natural killer cells in controlling growth and infiltration of AIDS-associated primary effusion lymphoma cells. Cancer Sci. 97:1381–1387. 2006. View Article : Google Scholar : PubMed/NCBI
19	Sun Z, Shi L, Zhang H, et al: Immuno modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer. Clin Immunol. 138:23–32. 2011. View Article : Google Scholar
20	Rao B, Han M, Wang L, et al: Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review. J Transl Med. 9:172011. View Article : Google Scholar : PubMed/NCBI
21	Jursik C, Prchal M, Grillari-Voglauer R, et al: Large-scale production and characterization of novel CD4⁺cytotoxic T cells with broad tumor specificity for immunotherapy. Mol Cancer Res. 7:339–353. 2009. View Article : Google Scholar : PubMed/NCBI
22	Iovino F, Meraviglia S, Spina M, et al: Immunotherapy targeting colon cancer stem cells. Immunotherapy. 3:97–106. 2011. View Article : Google Scholar : PubMed/NCBI
23	Sangiolo D: Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer. 2:363–368. 2011. View Article : Google Scholar : PubMed/NCBI
24	Barkholt L, Alici E, Conrad R, et al: Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy. 1:753–764. 2009. View Article : Google Scholar : PubMed/NCBI
25	Cruz CR, Hanley PJ, Liu H, et al: Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy. 12:743–749. 2010.PubMed/NCBI
26	Rabinowich H, Sedlmayr P, Herberman RB and Whiteside TL: Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells. Cell Immunol. 135:454–470. 1991. View Article : Google Scholar : PubMed/NCBI
27	Cho D, Kim SK and Carson WE III: NK cell-based immunotherapy for treating cancer: will it be promising? Korean J Hematol. 46:3–5. 2011. View Article : Google Scholar : PubMed/NCBI
28	Terme M, Ullrich E, Delahaye NF, et al: Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol. 9:486–494. 2008. View Article : Google Scholar : PubMed/NCBI
29	Zhou J and Zhong Y: Breast cancer immunotherapy. Cell Mol Immunol. 1:247–255. 2004.
30	McNeel DG: Cellular immunotherapies for prostate cancer. Biomed Pharmacother. 61:315–322. 2007. View Article : Google Scholar : PubMed/NCBI
31	Chu CS, Kim SH, June CH and Coukos G: Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther. 8:243–257. 2008. View Article : Google Scholar
32	Katipamula R and Markovic SN: Emerging therapies for melanoma. Expert Rev Anticancer Ther. 8:553–560. 2008. View Article : Google Scholar
33	Cooper LJ: Adoptive cellular immunotherapy for childhood malignancies. Bone Marrow Transplant. 41:183–192. 2008. View Article : Google Scholar : PubMed/NCBI
34	Stift A, Sachet M, Yagubian R, et al: Dendritic cell vaccination in medullary thyroid carcinoma. Clin Cancer Res. 10:2944–2953. 2004. View Article : Google Scholar : PubMed/NCBI
35	Wysocki PJ, Zolnierek J, Szczylik C, et al: Recent developments in renal cell cancer immunotherapy. Expert Opin Biol Ther. 7:727–737. 2007. View Article : Google Scholar : PubMed/NCBI